Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Children's Mercy Hospital Kansas City KBR |
---|---|
Information provided by: | Children's Mercy Hospital Kansas City |
ClinicalTrials.gov Identifier: | NCT00318097 |
McCune-Albright syndrome (MAS) is a syndrome caused by a genetic mutation that causes a specific protein in the body called a G protein to be constantly active. Children with McCune-Albright syndrome classically have early puberty, areas of increased skin pigmentation, and bone lesions resulting from the constant activity of the specific protein involved. Histamines are known to play a role in allergies and related allergic problems. The effects of histamines are controlled by the same G protein that is overly active in McCune-Albright syndrome. Thus, one could predict that patients with McCune-Albright may be at high risk for allergic problems. To date, no studies have documented any form of histamine excess or allergic difficulties in patients with McCune-Albright syndrome. However, the investigators have made the observation that a high percentage of their patients with MAS exhibit a range of allergic symptoms, from mild symptoms, to severe, life-threatening symptoms. The purpose of this study is to demonstrate increased histamine response by using a histamine skin test in patients with MAS. If increased reactions to histamines can be documented in MAS patients when compared to controls, severe and potentially life threatening allergic reactions in children with MAS could be anticipated and avoided.
Condition |
---|
McCune-Albright Syndrome |
Study Type: | Observational |
Study Design: | Screening, Cross-Sectional, Case Control, Prospective Study |
Official Title: | Histamine Responsiveness in Patients With McCune-Albright Syndrome |
Ages Eligible for Study: | up to 39 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Patients who exhibit two or more of the following clinical findings fit the diagnosis of MAS:
Exclusion Criteria:
Contact: Angela L Turpin, MD | 816-234-3804 | aturpin@cmh.edu |
Contact: Jill D Jacobson, MD | 816-234-3804 | jjacobson@cmh.edu |
United States, Missouri | |
Children's Mercy Hospitals and Clinics | Recruiting |
Kansas City, Missouri, United States, 64108 | |
Contact: Angela L Turpin, MD 816-234-3804 aturpin@cmh.edu | |
Contact: Jill D Jacobson, MD 816-234-3804 jjacobson@cmh.edu |
Principal Investigator: | Angela L Turpin, MD | Children's Mercy Hospital Kansas City |
Study ID Numbers: | 03 11-116 |
Study First Received: | April 24, 2006 |
Last Updated: | May 1, 2006 |
ClinicalTrials.gov Identifier: | NCT00318097 History of Changes |
Health Authority: | United States: Institutional Review Board |
McCune Albright Syndrome Histamine regulation |
Neurotransmitter Agents McCune Albright Syndrome Musculoskeletal Diseases Bone Diseases, Developmental Osteochondrodysplasias Fibrous Dysplasia of Bone |
Histamine phosphate Fibrous Dysplasia Fibrous Dysplasia, Polyostotic Bone Diseases Histamine |
Neurotransmitter Agents Disease Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Fibrous Dysplasia of Bone Osteochondrodysplasias Histamine Agents Fibrous Dysplasia, Polyostotic |
Bone Diseases Pharmacologic Actions Histamine Pathologic Processes Musculoskeletal Diseases Histamine Agonists Syndrome Bone Diseases, Developmental |